Sinopharm Group Co stock analysis
Sinopharm Group Co (X2S1) Stock Price & Analysis
X2S1 Stock Chart & Stats
- Day’s Range
- EUR 9.55 - EUR 9.55
- 52-Week Range
- EUR 8.05 - EUR 11.80
- Previous Close
- EUR 9.55
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 6.02B
- Enterprise Value
- EUR 23.42B
- Total Cash (Recent Filing)
- EUR 41.90B
- Total Debt (Recent Filing)
- EUR 81.32B
- Price to Earnings (P/E)
- 6.3
- Beta
- 0.33
- Next Earnings
- Mar 19, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.55%
Bulls Say, Bears Say
Bulls Say
Nationwide Healthcare Distribution Network
The nationwide distribution network gives Sinopharm broad access to institutional and retail healthcare customers. Its coverage across hospitals, clinics, pharmacies and providers supports recurring product flow and creates a durable platform for distributing medicines, devices and consumables at scale.
Broad Healthcare Product Portfolio
A broad product portfolio reduces reliance on any single healthcare category and allows the company to serve multiple customer needs through the same distribution infrastructure. This breadth can support customer retention, cross-selling and resilience as demand shifts across healthcare products.
Positive Cash Generation
Consistently positive operating and free cash flow indicates that reported earnings generally convert into funding capacity. Although recent momentum weakened, this cash-generation record supports ongoing operations, working-capital needs and capital allocation without relying entirely on external financing.
Bears Say
Recent Revenue Contraction
Recent revenue contraction marks a deterioration from the stronger growth seen during 2021–2023. If weaker sales persist, the company may have less operating leverage and reduced capacity to absorb distribution costs, while slower volume growth could limit improvement in earnings over the next several quarters.
Structural Margin Compression
Falling gross and EBITDA margins show that profitability has weakened beyond the recent revenue slowdown. Because distribution earnings are already modest, sustained margin pressure could materially constrain profit growth, reduce reinvestment capacity and leave less cushion against pricing or cost pressures.
Higher Leverage And Weaker Returns
The sharp year-over-year increase in leverage reduces financial flexibility at the same time that returns on equity have weakened. Higher debt exposure can make future funding and capital allocation more constrained, while lower ROE signals that the enlarged equity and asset base is generating less shareholder return.
Sinopharm Group Co News
X2S1 FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
What is Sinopharm Group Co’s market cap?
When is Sinopharm Group Co’s upcoming earnings report date?
How were Sinopharm Group Co’s earnings last quarter?
Is Sinopharm Group Co overvalued?
Does Sinopharm Group Co pay dividends?
What is Sinopharm Group Co’s EPS estimate?
How many shares outstanding does Sinopharm Group Co have?
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sinopharm Group Co?
What is the TipRanks Smart Score and how is it calculated?
Sinopharm Group Co Stock Smart Score
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Wanyong Lian
- Employees
- 94,910
- Website
- www.sinopharmgroup.com.cn
- Address
- Sinopharm Group Building, Shanghai, SH, 200023, CN
Sinopharm Group Co (X2S1) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 10 | 0 | 2 |





